Full Papers
Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry
O. Karadag1, B. Farisogullari2, B. Yagiz3, A. Erden4, Z. Ademoglu5, G. Kimyon6, N.S. Bilge7, O.C. Icacan8, L. Kilic9, B.N. Coskun10, E.D. Ersozlu11, O. Kucuksahin12, R. Mercan13, S.S. Koca14, E. Gonullu15, M. Cinar16, S. Akar17, H. Emmungil18, T. Kasifoglu19, C. Bes20, A. Omma21, Y. Pehlivan22, S. Kiraz23, I. Ertenli24, E. Dalkilic25, U. Kalyoncu26
- Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey. drokaradag@gmail.com
- Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Bursa Uludag University Faculty of Medicine, Health Application and Research Center, Bursa, Turkey.
- Clinic of Rheumatology, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Trakya University Faculty of Medicine, Edirne, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Hatay Mustafa Kemal University Tayfur Ata Sokmen Faculty of Medicine, Hatay, Turkey.
- Department of Rheumatology, Eskisehir Osmangazi University Health, Application and Research Hospital, Eskisehir, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Istanbul Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Bursa Uludag University Faculty of Medicine, Health Application and Research Center, Bursa, Turkey.
- Department of Rheumatology, Adana City Training and Research Hospital, Adana, Turkey.
- Clinic of Rheumatology, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Tekirdag Namik Kemal University Faculty of Medicine, Tekirdag, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Firat University Faculty of Medicine, Firat University Hospital, Elazig, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Sakarya University Faculty of Medicine, Sakarya, Turkey.
- Clinic of Rheumatology, University of Health Sciences Gulhane Training and Research Hospital, Ankara, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Izmir Katip Celebi University, Atatürk Education and Research Hospital, Izmir, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Trakya University Faculty of Medicine, Edirne, Turkey.
- Department of Rheumatology, Eskisehir Osmangazi University Health, Application and Research Hospital, Eskisehir, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Istanbul Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
- Ankara Bilkent City Hospital, Rheumatology Clinic, Ankara, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Bursa Uludag University Faculty of Medicine, Health Application and Research Center, Bursa, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Bursa Uludag University Faculty of Medicine, Health Application and Research Center, Bursa, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
CER16730
2024 Vol.42, N°1
PI 0130, PF 0137
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 37650346 [PubMed]
Received: 04/04/2023
Accepted : 17/07/2023
In Press: 29/08/2023
Published: 24/01/2024
Abstract
OBJECTIVES:
To evaluate the retention rate, treatment response and safety of tocilizumab (TCZ) as first-line biologic treatment in rheumatoid arthritis (RA) patients with inadequate response to disease-modifying anti-rheumatic drugs (DMARD-IR).
METHODS:
The TReasure Registry is a multicentre, web-based registry of RA and spondyloarthritis patients across Turkey. DMARD-IR RA patients who received TCZ as first-line biologic treatment were included in this registry for efficacy and safety. Demographic and clinical data, treatments, and adverse events were collected. Drug retention rate was estimated using Kaplan-Meier analysis.
RESULTS:
Among 642 RA patients who ever used TCZ, 258 DMARD-IR RA patients (male/female: 18.2%/81.8%, mean age, 54.41 years) received TCZ as first-line biologic. The median disease duration was 97 (range, 60–179) months and the median TCZ treatment duration was 15 (range, 6–28) months. At the 6th and 12th months of TCZ treatment, the decrease in disease activity scores from baseline was significant. The Kaplan-Meier analysis revealed the retention rate of TCZ at the 12th, 24th, 36th, and 60th months as 81.1%, 73.8%, 66.2%, and 63.6%, respectively. Fifty-seven (22%) patients discontinued TCZ; the main reason being primary or secondary inefficacy (n=29).
CONCLUSIONS:
Over 80% drug retention rate at 12th month of TCZ treatment in this real-world study was concordant with previously conducted TCZ clinical studies. Significant reductions not only in the disease activity score-28 but also in the simplified disease activity index (SDAI) and clinical disease activity index (CDAI) scores, along with health assessment questionnaire (HAQ) scores, supported the impact of TCZ in RA management with a good safety profile.
